AzTrials
AzTrials

Attention-Deficit/Hyperactivity DisorderPhase 4NCT04781140

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

A Phase 4 study testing 100mg SPN-812 in people with Attention-Deficit/Hyperactivity Disorder, run by Supernus Pharmaceuticals, Inc. at 54 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD. Read more about this study

Who is it for?
Ages 48 to 69 months
Conditions the study is for
Attention-Deficit/Hyperactivity Disorder
What is being tested?
100mg SPN-812
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
286 participants
Where
54 sitesUnited States
Study dates
19 Mar 2024to Jan 2028
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 48 to 69 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
  • Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
  • Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
  • Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
  • Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
  • Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
Show all 12Show fewer
  • Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
  • Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
  • Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
  • Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
  • Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
  • Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).

Who cannot join

  • Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
  • Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
  • History of Bipolar Disorder diagnosed in a first degree relative.
  • Has global development delay or intellectual disability by medical history.
  • Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
  • Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
Show all 16Show fewer
  • Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
  • Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
  • Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
  • Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
  • Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
  • Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
  • Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
  • Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
  • Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
  • Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).

Trial locations and contacts

54 sites in 1 country. Contact the study team or a site near you to ask about taking part.

54 sites in 1 country

United States54 sites, 39 recruiting
  • Advanced Research Center (ARC), Inc.

    Anaheim, California, 92805

    714-999-6688, contact@arctrials.com

    Recruiting
  • Advanced Discovery Research LLC

    Atlanta, Georgia, 30318

    470-777-8839, contact@advdiscovery.com

    Recruiting
  • Clinical Integrative Research Center of Atlanta

    Atlanta, Georgia, 30328

    678-705-7341

    Recruiting
  • Kennedy Krieger Institute

    Baltimore, Maryland, 21205

    443-923-3850

    Recruiting
  • Kentucky Pediatric/Adult Research

    Bardstown, Kentucky, 40004

    502-349-1569, kpar@kpar.us

    Recruiting
  • Houston Clinical Trials, LLC.

    Bellaire, Texas, 77401

    Withdrawn
  • Hassman Research Institute

    Berlin, New Jersey, 08009

    Withdrawn
  • Neurobehavioral Medicine Group

    Bloomfield Hills, Michigan, 48302

    248-290-5400, info@neurobmg.com

    Recruiting
  • Boston Children's Hospital

    Boston, Massachusetts, 02445

    617-355-1118, benamin.mills@childrens.harvard.edu

    617-919-6954

    Recruiting
  • IMMUNOe Research Centers

    Centennial, Colorado, 80112

    303-771-9000, verosinfo@veroshealth.com

    303-773-9000

    Recruiting
  • Cincinnati Children's Hospital and Medical Center

    Cincinnati, Ohio, 45229

    513-636-9763, ADHDResearch@cchmc.org

    Recruiting
  • Vertex Clinical Research, LLC

    Clermont, Florida, 34711

    Withdrawn
  • Luna Research Center

    Coral Gables, Florida, 33134

    305-613-7761

    Recruiting
  • Javara

    Dallas, Texas, 75230

    Terminated
  • CenExcel iResearch, LLC

    Decatur, Georgia, 30030

    404-537-1281

    Recruiting
  • Duke University

    Durham, North Carolina, 27705

    919-681-1100

    Recruiting
  • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Encino]

    Encino, California, 91316

    Withdrawn
  • Qualmedica Research, LLC.

    Evansville, Indiana, 47715

    Terminated
  • Preferred Research Partners-NWA, LLC

    Fayetteville, Arkansas, 72703

    Withdrawn
  • Precise Research Centers

    Flowood, Mississippi, 39232

    601-420-5812

    Recruiting
  • Sarkis Clinical Trials

    Gainesville, Florida, 32607

    Terminated
  • National Institute of Clinical Research (PICR)

    Garden Grove, California, 92844

    Terminated
  • Cyn3rgy Research

    Gresham, Oregon, 97030

    503-907-2179, support@cyn3rgy.com

    Recruiting
  • Penn State Health Medical Group - Psychiatry and Behavioral Health

    Hershey, Pennsylvania, 17033

    717-531-0003 ext. 287364, rmyers12@pennstatehealth.psu.edu

    717-531-5656

    Recruiting
  • Sun Valley Research Center

    Imperial, California, 92251

    760-545-0123, svrcinfo@sunvalleyb.com

    Recruiting
  • Med Clinical Research

    Irvington, New Jersey, 07111

    908-798-8373, info@medclinicalresearch.com

    Recruiting
  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida, 32256

    904-281-5757

    Recruiting
  • Accel Research Sites - Lakeland CRU

    Lakeland, Florida, 33803

    Terminated
  • Clinical Research of Southern Nevada, LLC.

    Las Vegas, Nevada, 89128

    702-750-0000, kluna.cpbm@gmail.com

    Recruiting
  • Preferred Research Partners, Inc.

    Little Rock, Arkansas, 72211

    501-553-9987, info@preferredresearchpartners.com

    Recruiting
  • Alliance Research

    Long Beach, California, 90807

    562-548-8500, Research@asclepes.com

    Recruiting
  • Clinical Neuroscience Solutions, Inc.

    Memphis, Tennessee, 38119

    901-843-1045

    Recruiting
  • Avantis Clinical Research LLC

    Miami, Florida, 33155

    305-515-9006, info@avantisclinicalresearch.com

    Recruiting
  • Jersey Shore University Medical Center

    Neptune City, New Jersey, 07753

    732-897-3640, andrew.layman@hmhn.org

    Recruiting
  • DelRicht Research (Touro Medical Center)

    New Orleans, Louisiana, 70115

    Terminated
  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10028

    Withdrawn
  • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Newport Beach]

    Newport Beach, California, 92660

    Withdrawn
  • Coastal Carolina Research Center

    North Charleston, South Carolina, 29405

    843-856-3784, CCRC@CoastalCarolinaResearch.com

    Recruiting
  • Medical Research Group of Central Florida

    Orange City, Florida, 32763

    386-775-7627

    Recruiting
  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida, 32801

    407-425-5100, orlinfo@cnshealthcare.com

    Recruiting
  • APG Research LLC

    Orlando, Florida, 32803

    407-423-7149 ext. 166, kkenworthyapg@gmail.com

    407-423-7149 ext. 165

    Recruiting
  • Qualmedica Research, LLC.

    Owensboro, Kentucky, 42301

    Terminated
  • Clinical Research Partners, LLC

    Petersburg, Virginia, 23805

    804-921-9592, Recruitment@ClinicalResearchRVA.com

    Recruiting
  • AIM Trials, LLC

    Plano, Texas, 75093

    469-364-8804, info@aimtrials.com

    214-856-2778

    Recruiting
  • DelRicht Research

    Prairieville, Louisiana, 70769

    225-412-0316, info@delricht.com

    Recruiting
  • Virginia Commonwealth University, Virginia Treatment Center for Children

    Richmond, Virginia, 23220

    804-628-8736

    Recruiting
  • The Center for Clinical Trials, Inc.

    Saraland, Alabama, 36571

    251-341-7021, info@thecenterforclinicaltrials.com

    Recruiting
  • CenExel iResearch, LLC.

    Savannah, Georgia, 31405

    912-744-0800

    Recruiting
  • Coastal Pediatric Research

    Summerville, South Carolina, 29486

    843-870-2225, info.research@cpakids.com

    Recruiting
  • D&H Tamarac Research Center

    Tamarac, Florida, 33321

    786-375-6210, info@dhnrc.com

    Recruiting
  • Family Psych of The Woodlands

    The Woodlands, Texas, 77381

    281-367-1015, info@woodlandspsych.com

    Recruiting
  • Hope Research Network, LLC.

    Virginia Gardens, Florida, 33166

    786-953-8858, info@hoperesearchnetwork.com

    Recruiting
  • CincyScience

    West Chester, Ohio, 45069

    Withdrawn
  • Pediatric Neurology and Epilepsy Specialists

    Winter Park, Florida, 32789

    407-293-1122 ext. 121, ARiveraDelValle@pediatricneurologyandepilepsy.com

    407-293-1122 ext. 126, DHubert@pediatricneurologyandepilepsy.com

    Recruiting

Other trials in United States

About this study

Official title: A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 Years Old) With Attention-Deficit/Hyperactivity Disorder (ADHD)

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The total duration of the study is up to 10 weeks.

Being tested
100mg SPN-812, Placebo
Keywords
ADHD
Medical subject headings
Attention Deficit Disorder with Hyperactivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 100mg SPN-812Drug

    Also called SPN-812

    100mg SPN-812 will be administered once daily and compared to Placebo

  • PlaceboDrug

    Placebo will be administered once daily

Study groups in NCT04781140
Study groupRoleWhat they receive
PlaceboPlacebo comparatorPlacebo, qd
Receives: Drug: Placebo
SPN-812ExperimentalSPN-812, qd
Receives: Drug: 100mg SPN-812

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)

    The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I", 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline ADHD-RS-IV-P Total Score (<0) represents a better outcome.

    Measured: Baseline and Week 6

Secondary outcomes (7)
  1. Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score at End of Study (Week 6)

    The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients (the higher the score, the more severe the overall ADHD symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (<0) represents a better outcome.

    Measured: Baseline and Week 6

  2. Clinical Global Impression of Change (CGI-C) Score at End of Study (Week 6)

    The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score <4 represents a better outcome.

    Measured: Week 6

  3. Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Hyperactivity/Impulsivity Subscale Score at End of Study (Week 6)

    The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine H/I items yields the raw H/I subscale score (range: 0-27; the higher the H/I subscale score, the more severe the H/I symptoms). Post-baseline raw H/I subscale scores are converted to a change from baseline score. A lower change from baseline H/I subscale score (<0) represents a better outcome.

    Measured: Baseline and Week 6

  4. Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Inattention Subscale Score at End of Study (Week 6)

    The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine IA items yields the raw IA subscale score (range: 0-27; the higher the IA subscale score, the more severe the IA symptoms). Post-baseline raw IA subscale scores are converted to a change from baseline score. A lower change from baseline IA subscale score (<0) represents a better outcome.

    Measured: Baseline and Week 6

  5. Clinical Global Impression of Severity (CGI-S) Responder Rate (percentage of subjects with CGI-S score of 1 or 2) at End of Study (Week 6)

    The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients. The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

    Measured: Baseline and Week 6

  6. Clinical Global Impression of Change (CGI-C) Responder Rate (percentage of subjects with CGI-C score of 1 or 2) at End of Study (Week 6)

    The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

    Measured: Week 6

  7. Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Responder Rate (percentage of subjects with ≥ 50% Reduction in Change from Baseline) at End of Study (Week 6)

    The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two 9 item subscales: inattention and hyperactivity-impulsivity. The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale; 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. Sum of 18 ratings yields the Total score (range: 0-54; higher score represents severer symptoms). Percent reduction is calculated for the ADHD-RS-IV-P score: [("Post-baseline"-"Baseline")/"Baseline"] x 100; range: 0 to 100%; a "responder" is a subject with a 50% or greater reduction in change from baseline Total score. Responder rate (percent of responders) is calculated: ["number of 'responders' (m)"/ "number of subjects analyzed" (n)] X 100; range: 0 to 100%. A Responder Rate greater than 50%, represents more "responders" versus "nonresponders".

    Measured: Baseline and Week 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2021
  2. Study start19 Mar 2024
  3. Primary completionJan 2028 (estimated)
  4. Study completionJan 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
286 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04781140
Sponsor's protocol ID
812P401
Status last verified
Oct 2026
First submitted
26 Feb 2021
Last updated
5 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing 100mg SPN-812 in people with Attention-Deficit/Hyperactivity Disorder, run by Supernus Pharmaceuticals, Inc. at 54 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 5 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 54 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Olivia Elbaum (301-838-2500, clinicaltrials@supernus.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6) (time frame: Baseline and Week 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in